Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions.

Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, Zhang J, Highsmith WE, Halling KC, Kipp BR.

Hum Pathol. 2013 Jul;44(7):1216-22. doi: 10.1016/j.humpath.2012.11.006. Epub 2013 Feb 4.

PMID:
23391413
[PubMed - indexed for MEDLINE]
2.

Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.

Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, Ellisen LW, Zhu AX, Iafrate AJ.

Oncologist. 2012;17(1):72-9. doi: 10.1634/theoncologist.2011-0386. Epub 2011 Dec 16.

PMID:
22180306
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.

Kipp BR, Voss JS, Kerr SE, Barr Fritcher EG, Graham RP, Zhang L, Highsmith WE, Zhang J, Roberts LR, Gores GJ, Halling KC.

Hum Pathol. 2012 Oct;43(10):1552-8. doi: 10.1016/j.humpath.2011.12.007. Epub 2012 Apr 12.

PMID:
22503487
[PubMed - indexed for MEDLINE]
4.

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.

Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR, Factor VM, Thorgeirsson SS.

Gastroenterology. 2012 Apr;142(4):1021-1031.e15. doi: 10.1053/j.gastro.2011.12.005. Epub 2011 Dec 13.

PMID:
22178589
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas.

Gwak GY, Yoon JH, Shin CM, Ahn YJ, Chung JK, Kim YA, Kim TY, Lee HS.

J Cancer Res Clin Oncol. 2005 Oct;131(10):649-52. Epub 2005 Oct 20.

PMID:
16032426
[PubMed - indexed for MEDLINE]
6.

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.

Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, Andersen JB, Jiang W, Savich GL, Tan TX, Auman JT, Hoskins JM, Misher AD, Moser CD, Yourstone SM, Kim JW, Cibulskis K, Getz G, Hunt HV, Thorgeirsson SS, Roberts LR, Ye D, Guan KL, Xiong Y, Qin LX, Chiang DY.

Oncogene. 2013 Jun 20;32(25):3091-100. doi: 10.1038/onc.2012.315. Epub 2012 Jul 23.

PMID:
22824796
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Molecular and immunohistochemical analysis of intraductal papillary neoplasms of the biliary tract.

Abraham SC, Lee JH, Hruban RH, Argani P, Furth EE, Wu TT.

Hum Pathol. 2003 Sep;34(9):902-10.

PMID:
14562286
[PubMed - indexed for MEDLINE]
8.

Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma.

Deshpande V, Nduaguba A, Zimmerman SM, Kehoe SM, Macconaill LE, Lauwers GY, Ferrone C, Bardeesy N, Zhu AX, Hezel AF.

BMC Cancer. 2011 Feb 8;11:60. doi: 10.1186/1471-2407-11-60.

PMID:
21303542
[PubMed - indexed for MEDLINE]
Free PMC Article
9.
10.

Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.

McKay SC, Unger K, Pericleous S, Stamp G, Thomas G, Hutchins RR, Spalding DR.

HPB (Oxford). 2011 May;13(5):309-19. doi: 10.1111/j.1477-2574.2010.00286.x. Epub 2011 Mar 10.

PMID:
21492330
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.

Xu RF, Sun JP, Zhang SR, Zhu GS, Li LB, Liao YL, Xie JM, Liao WJ.

Biomed Pharmacother. 2011 Feb;65(1):22-6. doi: 10.1016/j.biopha.2010.06.009. Epub 2010 Nov 3.

PMID:
21051183
[PubMed - indexed for MEDLINE]
12.

Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.

Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, Hauss J, Wittekind C.

Gut. 2003 May;52(5):706-12.

PMID:
12692057
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.

Gao Q, Zhao YJ, Wang XY, Guo WJ, Gao S, Wei L, Shi JY, Shi GM, Wang ZC, Zhang YN, Shi YH, Ding J, Ding ZB, Ke AW, Dai Z, Wu FZ, Wang H, Qiu ZP, Chen ZA, Zhang ZF, Qiu SJ, Zhou J, He XH, Fan J.

Gastroenterology. 2014 May;146(5):1397-407. doi: 10.1053/j.gastro.2014.01.062. Epub 2014 Feb 4.

PMID:
24503127
[PubMed - indexed for MEDLINE]
14.

p53 Mutations in human cholangiocarcinoma: a review.

Khan SA, Thomas HC, Toledano MB, Cox IJ, Taylor-Robinson SD.

Liver Int. 2005 Aug;25(4):704-16. Review.

PMID:
15998419
[PubMed - indexed for MEDLINE]
15.

Genetics of hepatobiliary carcinogenesis.

Nault JC, Zucman-Rossi J.

Semin Liver Dis. 2011 May;31(2):173-87. doi: 10.1055/s-0031-1276646. Epub 2011 May 2. Review.

PMID:
21538283
[PubMed - indexed for MEDLINE]
16.

Cell adhesion molecules P-cadherin and CD24 are markers for carcinoma and dysplasia in the biliary tract.

Riener MO, Vogetseder A, Pestalozzi BC, Clavien PA, Probst-Hensch N, Kristiansen G, Jochum W.

Hum Pathol. 2010 Nov;41(11):1558-65. doi: 10.1016/j.humpath.2009.12.016.

PMID:
20621328
[PubMed - indexed for MEDLINE]
17.

Viral hepatitis is associated with intrahepatic cholangiocarcinoma with cholangiolar differentiation and N-cadherin expression.

Yu TH, Yuan RH, Chen YL, Yang WC, Hsu HC, Jeng YM.

Mod Pathol. 2011 Jun;24(6):810-9. doi: 10.1038/modpathol.2011.41. Epub 2011 Mar 18.

PMID:
21423153
[PubMed - indexed for MEDLINE]
Free Article
18.

TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.

Della Torre G, Pasquini G, Pilotti S, Alasio L, Civelli E, Cozzi G, Milella M, Salvetti M, Pierotti MA, Severini A.

Diagn Mol Pathol. 2000 Mar;9(1):41-6.

PMID:
10718212
[PubMed - indexed for MEDLINE]
19.

IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.

Borger DR, Zhu AX.

Expert Rev Anticancer Ther. 2012 May;12(5):543-6. doi: 10.1586/era.12.32. No abstract available.

PMID:
22594888
[PubMed - indexed for MEDLINE]
20.

Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.

Kim BH, Cho NY, Choi M, Lee S, Jang JJ, Kang GH.

Arch Pathol Lab Med. 2007 Jun;131(6):923-30.

PMID:
17550320
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk